The approval was based on data from 3 clinical studies that assessed the antihypertensive effect of valsartan in 290 children 1 to less than 6 years of age. The Food and Drug Administration (FDA) has ...

Generic Diovan is coming. The Wall Street Journal reports that generics drugmaker Ranbaxy has scored an FDA approval to manufacture an off-brand version of the blood pressure medication. The drug will ...

WASHINGTON/MUMBAI (Reuters) - Ranbaxy Laboratories Ltd (RANB.NS) has received approval from the U.S. Food and Drug Administration (FDA) to launch a cheaper copy of Novartis AG's blood pressure pill ...

Although the patent on valsartan (Diovan, Novartis) expired last Friday, a generic version of the popular antihypertensive drug has yet to make it to market. By contrast, a generic version of Diovan ...

A few years ago India’s Alkem Laboratories was in the hot seat with the FDA, having had several plants cited by inspectors. Today it is in the driver’s seat after the agency approved its new generic ...

Pfizer's ($PFE) success with co-pay coupons has encouraged other blockbuster-losing Big Pharmas to follow suit. Have the others been able to replicate Pfizer's ...

Ranbaxy’s export woes may be hurting its own sales, but the Indian generics firm is actually making life easier for Novartis. Ranbaxy currently holds exclusive rights to sell the generic version of ...

ZURICH (Reuters) - Novartis (NOVN.VX) plans to axe around 500 jobs in shutting a U.S. plant that makes its blood pressure pill Diovan, marking the second reorganization of its operations in as many ...

Diovan HCT is used for the treatment of high blood pressure (:HBP). According to IMS Health, Diovan HCT (80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg tablets), generated US revenues ...

This latest evaluation is part of a giant clinical trials program for Diovan that Novartis is conducting under a strategy to widen the drug’s market opportunity as well as extend its patent armour, ...

Following a long series of accusations, retractions, and the resignation of a prominent professor, it now is clear that data from a large Japanese study of valsartan (Diovan, Novartis) was fabricated.

Credit: Getty Images. The approval was based on data from 3 clinical studies that assessed the antihypertensive effect of valsartan in 290 children 1 to less than 6 years of age. The Food and Drug ...